ARS Pharmaceuticals (SPRY) Set to Post Quarterly Earnings on Thursday

ARS Pharmaceuticals (NASDAQ:SPRY) is expected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect ARS Pharmaceuticals to announce earnings of ($0.34) per share and revenue of $41.99 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.15). The firm had revenue of $33.66 million during the quarter, compared to analyst estimates of $31.32 million. ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%. On average, analysts expect ARS Pharmaceuticals to post ($1.91) EPS for the current fiscal year and ($0.88) EPS for the next fiscal year.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ SPRY traded down $0.03 during trading hours on Tuesday, hitting $3.02. 499,490 shares of the stock were exchanged, compared to its average volume of 1,703,036. The company has a debt-to-equity ratio of 13.72, a current ratio of 3.48 and a quick ratio of 3.28. The company’s 50 day moving average is $4.52 and its 200 day moving average is $7.38. The firm has a market capitalization of $300.83 million, a P/E ratio of -1.38 and a beta of 0.98. ARS Pharmaceuticals has a one year low of $2.91 and a one year high of $13.15.

Analyst Upgrades and Downgrades

SPRY has been the subject of a number of research analyst reports. Weiss Ratings lowered shares of ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Leerink Partners set a $15.00 price target on ARS Pharmaceuticals in a research report on Tuesday, September 8th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $25.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product is neffy (epinephrine nasal spray), a needle-free alternative to injectable epinephrine designed for the emergency treatment of allergic reactions, including anaphylaxis.

Neffy was approved by the U.S. Food and Drug Administration in 2024 for adults and pediatric patients who weigh at least 30 kilograms. The product is intended to provide rapid, convenient administration without requiring a syringe or injector, which may help address barriers associated with the use of traditional epinephrine auto-injectors.